THE ANALYSIS STUDY OF ASSOCIATION OF TYPE 2 DIABETES MELLITUS AND SKIN CANCER: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/xdw7fm80Keywords:
Diabetes, skin cancer, correlation, incidence, NMSCAbstract
Background: The correlation between type 2 diabetes and skin cancer has been established, with elevated blood glucose levels and increased insulin levels associated with a higher risk of certain malignancies, such as nonmelanoma skin cancer. However, the impact of insulin therapy on cancer risk in individuals with type 2 diabetes is generally not significant. Understanding this correlation can help develop effective strategies for managing both conditions.
Methods: Following PRISMA 2020 guidelines, this systematic review concentrated on full-text English literature published between 2014 and 2024. Editorials and review articles that appeared in the same journal as the submission were not accepted without a DOI. A number of websites, including ScienceDirect, PubMed, and SagePub, were utilized to gather the literature.
Result: The study looked at more than 100 publications using reputable sources including Science Direct, SagePub, and PubMed. After it was decided that eight publications needed greater investigation, a more extensive review of the entire literature was carried out.
Conclusion: The incidence of skin cancer in diabetic individuals is higher in those aged 60 and older, with males more likely to develop non-melanoma skin cancer (NMSC) and melanoma. Risk factors include sex, comorbidities, immunosuppression status, and socioeconomic status. Insulin therapy can lower the risk of NMSC, but further studies are needed to understand differences in incidence.
References
Massouh, N., Jaffa, A. A., & Jaffa, M. A. (2024). Role of Insulin Use and Social Determinants of Health on Nonmelanoma Skin Cancer: Results From the Behavioral Risk Factor Surveillance System. Cancer control : journal of the Moffitt Cancer Center, 31, 10732748241249896. https://doi.org/10.1177/10732748241249896
Dobrică, E. C., Banciu, M. L., Kipkorir, V., Khazeei Tabari, M. A., Cox, M. J., Simhachalam Kutikuppala, L. V., & Găman, M. A. (2022). Diabetes and skin cancers: Risk factors, molecular mechanisms and impact on prognosis. World journal of clinical cases, 10(31), 11214–11225. https://doi.org/10.12998/wjcc.v10.i31.11214
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010). Diabetes and cancer: a consensus report. Diabetes care, 33(7), 1674–1685. https://doi.org/10.2337/dc10-0666
Sasazuki, S., Charvat, H., Hara, A., Wakai, K., Nagata, C., Nakamura, K., Tsuji, I., Sugawara, Y., Tamakoshi, A., Matsuo, K., Oze, I., Mizoue, T., Tanaka, K., Inoue, M., Tsugane, S., & Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan (2013). Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer science, 104(11), 1499–1507. https://doi.org/10.1111/cas.12241
Tseng, H. W., Shiue, Y. L., Tsai, K. W., Huang, W. C., Tang, P. L., & Lam, H. C. (2016). Risk of skin cancer in patients with diabetes mellitus: A nationwide retrospective cohort study in Taiwan. Medicine, 95(26), e4070. https://doi.org/10.1097/MD.0000000000004070
Wotton, C. J., Yeates, D. G., & Goldacre, M. J. (2011). Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia, 54(3), 527–534. https://doi.org/10.1007/s00125-010-1987-2
Brownlee M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865), 813–820. https://doi.org/10.1038/414813a
Adams, T. E., McKern, N. M., & Ward, C. W. (2004). Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth factors (Chur, Switzerland), 22(2), 89–95. https://doi.org/10.1080/08977190410001700998
Vicentini, M., Ballotari, P., Venturelli, F., Ottone, M., Manicardi, V., Gallo, M., Greci, M., Pinotti, M., Pezzarossi, A., & Giorgi Rossi, P. (2022). Impact of Insulin Therapies on Cancer Incidence in Type 1 and Type 2 Diabetes: A Population-Based Cohort Study in Reggio Emilia, Italy. Cancers, 14(11), 2719. https://doi.org/10.3390/cancers14112719
Chen, C. J., You, S. L., Lin, L. H., Hsu, W. L., & Yang, Y. W. (2002). Cancer epidemiology and control in Taiwan: a brief review. Japanese journal of clinical oncology, 32 Suppl, S66–S81. https://doi.org/10.1093/jjco/hye138
Chiang, C. J., Chen, Y. C., Chen, C. J., You, S. L., Lai, M. S., & Taiwan Cancer Registry Task Force (2010). Cancer trends in Taiwan. Japanese journal of clinical oncology, 40(10), 897–904. https://doi.org/10.1093/jjco/hyq057
Eisemann, N., Waldmann, A., Geller, A. C., Weinstock, M. A., Volkmer, B., Greinert, R., Breitbart, E. W., & Katalinic, A. (2014). Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. The Journal of investigative dermatology, 134(1), 43–50. https://doi.org/10.1038/jid.2013.304
Urban, K., Mehrmal, S., Uppal, P., Giesey, R. L., & Delost, G. R. (2021). The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990-2017. JAAD international, 2, 98–108. https://doi.org/10.1016/j.jdin.2020.10.013
Tang, H., Yang, K., Song, Y., & Han, J. (2018). Meta-analysis of the association between sodium-glucose cotransporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes. Diabetes, obesity & metabolism, 20(12), 2919–2924. https://doi.org/10.1111/dom.13474
Lyundup, A. V., Balyasin, M. V., Maksimova, N. V., Kovina, M. V., Krasheninnikov, M. E., Dyuzheva, T. G., Yakovenko, S. A., Appolonova, S. A., Schiöth, H. B., & Klabukov, I. D. (2022). Misdiagnosis of diabetic foot ulcer in patients with undiagnosed skin malignancies. International wound journal, 19(4), 871–887. https://doi.org/10.1111/iwj.13688
Nwabudike, L. C., Oproiu, A. M., Dogaru, I. M., Costache, M., Onisor, C., & Tatu, A. L. (2021). Therapy Delayed is Therapy Denied: A Case Report of Melanoma Misdiagnosed as Diabetic Foot Ulcer. Clinical, cosmetic and investigational dermatology, 14, 1909–1912. https://doi.org/10.2147/CCID.S337545
Pradhan, R., Yu, O. H. Y., Platt, R. W., & Azoulay, L. (2023). Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. BMJ open diabetes research & care, 11(6), e003550. https://doi.org/10.1136/bmjdrc-2023-003550
Ren, M. Y., Shi, Y. J., Lu, W., Fan, S. S., Tao, X. H., & Ding, Y. (2023). Facial Merkel cell carcinoma in a patient with diabetes and hepatitis B: A case report. World journal of clinical cases, 11(17), 4179–4186. https://doi.org/10.12998/wjcc.v11.i17.4179
Pradhan, R., Yu, O. H. Y., Platt, R. W., & Azoulay, L. (2024). Glucagon like peptide-1 receptor agonists and the
risk of skin cancer among patients with type 2 diabetes: Population-based cohort study. Diabetic medicine : a journal of the British Diabetic Association, 41(4), e15248. https://doi.org/10.1111/dme.15248
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2020). Social Determinants of Health and Diabetes: A Scientific Review. Diabetes care, 44(1), 258–279. Advance online publication. https://doi.org/10.2337/dci20-0053
Harvey, V. M., Patel, H., Sandhu, S., Wallington, S. F., & Hinds, G. (2014). Social determinants of racial and ethnic disparities in cutaneous melanoma outcomes. Cancer control : journal of the Moffitt Cancer Center, 21(4), 343–349. https://doi.org/10.1177/107327481402100411
Busek, P., Duke-Cohan, J. S., & Sedo, A. (2022). Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?. Cancers, 14(9), 2072. https://doi.org/10.3390/cancers14092072
Kuo, P. T., Zeng, Z., Salim, N., Mattarollo, S., Wells, J. W., & Leggatt, G. R. (2018). The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer. Frontiers in medicine, 5, 271. https://doi.org/10.3389/fmed.2018.00271
FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC): Liraglutide-LEADER. 2017.
Ederaine, S. A., Dominguez, J. L., Harvey, J. A., Mangold, A. R., Cook, C. B., Kosiorek, H., Buras, M., Coppola, K., & Karlin, N. J. (2021). Survival and glycemic control in patients with co-existing squamous cell carcinoma and diabetes mellitus. Future science OA, 7(5), FSO683. https://doi.org/10.2144/fsoa-2020-0150
Becker, J. C., Stang, A., Hausen, A. Z., Fischer, N., DeCaprio, J. A., Tothill, R. W., Lyngaa, R., Hansen, U. K., Ritter, C., Nghiem, P., Bichakjian, C. K., Ugurel, S., & Schrama, D. (2018). Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer immunology, immunotherapy : CII, 67(3), 341–351. https://doi.org/10.1007/s00262-017-2099-3
Sahi, H., Sihto, H., Artama, M., Koljonen, V., Böhling, T., & Pukkala, E. (2017). History of chronic inflammatory disorders increases the risk of Merkel cell carcinoma, but does not correlate with Merkel cell polyomavirus infection. British journal of cancer, 116(2), 260–264. https://doi.org/10.1038/bjc.2016.391
Bradford, P. T., Goldstein, A. M., McMaster, M. L., & Tucker, M. A. (2009). Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Archives of dermatology, 145(4), 427–434. https://doi.org/10.1001/archdermatol.2008.609
Arrington, J. H., 3rd, Reed, R. J., Ichinose, H., & Krementz, E. T. (1977). Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. The American journal of surgical pathology, 1(2), 131–143.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
